Cephalosporin-glycopeptide combinations for use against clinical methicillin-resistant staphylococcus aureus isolates: Enhanced in vitro antibacterial activity

Hung Jen Tang, Chih Cheng Lai, Chi Chung Chen, Chun Cheng Zhang, Tzu Chieh Weng, Wen Liang Yu, Hung Jui Chen, Yu Hsin Chiu, Wen Chien Ko, Yin Ching Chuang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The empirical combination of both a beta-lactam and glycopeptide to counter potential staphylococcal pathogens may improve the clinical outcomes for cases of Staphylococcus aureus bacteremia. We reported comparative in vitro studies of combination effects of different cephalosporins (i.e., cefazolin, cefmetazole, cefotaxime, and cefepime) combined with glycopeptides for 34 randomly selected methicillin-resistant S. aureus (MRSA) isolates by three methods, including the checkerboard, time-killing, and combination MIC measurement methods. Thirteen SCCmec type III isolates with a cefazolin MIC of = 128 μg/mL were classified as the high-cefazolin MIC (HCM) group, whereas 13 SCCmec type IV and 8 SCCmec type V isolates were classified as the low-cefazolin MIC (LCM) group. With the checkerboard method, synergism was present for vancomycin-based combinations at 30.8-69.2 and 13.6-66.7%, as well as teicoplanin-based combinations of 38.5-84.6 and 0-47.6%, of the HCM and LCM isolates, respectively. No antagonism was noted. The in vitro inhibitory activity was evident even at a low concentration of 1/512x MIC of cephalosporin combined with sub-inhibitory concentrations (1/2x MIC) of a glycopeptide. With time-killing assays, synergism was noted at 1/2x or 1x susceptible breakpoint concentrations (SBCs) of a cephalosporin combined with 1/4 or 1/2 MIC of a glycopeptide. In the presence of 1/2 SBC of a cephalosporin, vancomycin or teicoplanin MICs decreased an average of 2.0- to 6.6- or 1.6- to 5.5-fold, respectively. With 8 μg/mL cephalosporin, the decline of glycopeptide MICs was most obvious in the presence of cefmetazole. In conclusion, cephalosporin-glycopeptide combinations at clinically achievable concentrations can exhibit in vitro synergistic antibacterial activity against clinical MRSA isolates. Such combinations require more clinical data to support their application for use in human MRSA infections.

Original languageEnglish
Article number884
JournalFrontiers in Microbiology
Volume8
Issue numberMAY
DOIs
Publication statusPublished - May 18 2017
Externally publishedYes

Fingerprint

Cefazolin
Glycopeptides
Cephalosporins
Methicillin-Resistant Staphylococcus aureus
Cefmetazole
Teicoplanin
Vancomycin
Cefotaxime
beta-Lactams
Bacteremia
Staphylococcus aureus
In Vitro Techniques
Infection

Keywords

  • Cefazolin
  • Cefepime
  • Cefmetazole
  • Cefotaxime
  • Combination therapy
  • Glycopeptides
  • MRSA
  • Synergism

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

Cephalosporin-glycopeptide combinations for use against clinical methicillin-resistant staphylococcus aureus isolates : Enhanced in vitro antibacterial activity. / Tang, Hung Jen; Lai, Chih Cheng; Chen, Chi Chung; Zhang, Chun Cheng; Weng, Tzu Chieh; Yu, Wen Liang; Chen, Hung Jui; Chiu, Yu Hsin; Ko, Wen Chien; Chuang, Yin Ching.

In: Frontiers in Microbiology, Vol. 8, No. MAY, 884, 18.05.2017.

Research output: Contribution to journalArticle

Tang, Hung Jen ; Lai, Chih Cheng ; Chen, Chi Chung ; Zhang, Chun Cheng ; Weng, Tzu Chieh ; Yu, Wen Liang ; Chen, Hung Jui ; Chiu, Yu Hsin ; Ko, Wen Chien ; Chuang, Yin Ching. / Cephalosporin-glycopeptide combinations for use against clinical methicillin-resistant staphylococcus aureus isolates : Enhanced in vitro antibacterial activity. In: Frontiers in Microbiology. 2017 ; Vol. 8, No. MAY.
@article{bd084dbb1a434406a9fb62162af25b9e,
title = "Cephalosporin-glycopeptide combinations for use against clinical methicillin-resistant staphylococcus aureus isolates: Enhanced in vitro antibacterial activity",
abstract = "The empirical combination of both a beta-lactam and glycopeptide to counter potential staphylococcal pathogens may improve the clinical outcomes for cases of Staphylococcus aureus bacteremia. We reported comparative in vitro studies of combination effects of different cephalosporins (i.e., cefazolin, cefmetazole, cefotaxime, and cefepime) combined with glycopeptides for 34 randomly selected methicillin-resistant S. aureus (MRSA) isolates by three methods, including the checkerboard, time-killing, and combination MIC measurement methods. Thirteen SCCmec type III isolates with a cefazolin MIC of = 128 μg/mL were classified as the high-cefazolin MIC (HCM) group, whereas 13 SCCmec type IV and 8 SCCmec type V isolates were classified as the low-cefazolin MIC (LCM) group. With the checkerboard method, synergism was present for vancomycin-based combinations at 30.8-69.2 and 13.6-66.7{\%}, as well as teicoplanin-based combinations of 38.5-84.6 and 0-47.6{\%}, of the HCM and LCM isolates, respectively. No antagonism was noted. The in vitro inhibitory activity was evident even at a low concentration of 1/512x MIC of cephalosporin combined with sub-inhibitory concentrations (1/2x MIC) of a glycopeptide. With time-killing assays, synergism was noted at 1/2x or 1x susceptible breakpoint concentrations (SBCs) of a cephalosporin combined with 1/4 or 1/2 MIC of a glycopeptide. In the presence of 1/2 SBC of a cephalosporin, vancomycin or teicoplanin MICs decreased an average of 2.0- to 6.6- or 1.6- to 5.5-fold, respectively. With 8 μg/mL cephalosporin, the decline of glycopeptide MICs was most obvious in the presence of cefmetazole. In conclusion, cephalosporin-glycopeptide combinations at clinically achievable concentrations can exhibit in vitro synergistic antibacterial activity against clinical MRSA isolates. Such combinations require more clinical data to support their application for use in human MRSA infections.",
keywords = "Cefazolin, Cefepime, Cefmetazole, Cefotaxime, Combination therapy, Glycopeptides, MRSA, Synergism",
author = "Tang, {Hung Jen} and Lai, {Chih Cheng} and Chen, {Chi Chung} and Zhang, {Chun Cheng} and Weng, {Tzu Chieh} and Yu, {Wen Liang} and Chen, {Hung Jui} and Chiu, {Yu Hsin} and Ko, {Wen Chien} and Chuang, {Yin Ching}",
year = "2017",
month = "5",
day = "18",
doi = "10.3389/fmicb.2017.00884",
language = "English",
volume = "8",
journal = "Frontiers in Microbiology",
issn = "1664-302X",
publisher = "Frontiers Media S. A.",
number = "MAY",

}

TY - JOUR

T1 - Cephalosporin-glycopeptide combinations for use against clinical methicillin-resistant staphylococcus aureus isolates

T2 - Enhanced in vitro antibacterial activity

AU - Tang, Hung Jen

AU - Lai, Chih Cheng

AU - Chen, Chi Chung

AU - Zhang, Chun Cheng

AU - Weng, Tzu Chieh

AU - Yu, Wen Liang

AU - Chen, Hung Jui

AU - Chiu, Yu Hsin

AU - Ko, Wen Chien

AU - Chuang, Yin Ching

PY - 2017/5/18

Y1 - 2017/5/18

N2 - The empirical combination of both a beta-lactam and glycopeptide to counter potential staphylococcal pathogens may improve the clinical outcomes for cases of Staphylococcus aureus bacteremia. We reported comparative in vitro studies of combination effects of different cephalosporins (i.e., cefazolin, cefmetazole, cefotaxime, and cefepime) combined with glycopeptides for 34 randomly selected methicillin-resistant S. aureus (MRSA) isolates by three methods, including the checkerboard, time-killing, and combination MIC measurement methods. Thirteen SCCmec type III isolates with a cefazolin MIC of = 128 μg/mL were classified as the high-cefazolin MIC (HCM) group, whereas 13 SCCmec type IV and 8 SCCmec type V isolates were classified as the low-cefazolin MIC (LCM) group. With the checkerboard method, synergism was present for vancomycin-based combinations at 30.8-69.2 and 13.6-66.7%, as well as teicoplanin-based combinations of 38.5-84.6 and 0-47.6%, of the HCM and LCM isolates, respectively. No antagonism was noted. The in vitro inhibitory activity was evident even at a low concentration of 1/512x MIC of cephalosporin combined with sub-inhibitory concentrations (1/2x MIC) of a glycopeptide. With time-killing assays, synergism was noted at 1/2x or 1x susceptible breakpoint concentrations (SBCs) of a cephalosporin combined with 1/4 or 1/2 MIC of a glycopeptide. In the presence of 1/2 SBC of a cephalosporin, vancomycin or teicoplanin MICs decreased an average of 2.0- to 6.6- or 1.6- to 5.5-fold, respectively. With 8 μg/mL cephalosporin, the decline of glycopeptide MICs was most obvious in the presence of cefmetazole. In conclusion, cephalosporin-glycopeptide combinations at clinically achievable concentrations can exhibit in vitro synergistic antibacterial activity against clinical MRSA isolates. Such combinations require more clinical data to support their application for use in human MRSA infections.

AB - The empirical combination of both a beta-lactam and glycopeptide to counter potential staphylococcal pathogens may improve the clinical outcomes for cases of Staphylococcus aureus bacteremia. We reported comparative in vitro studies of combination effects of different cephalosporins (i.e., cefazolin, cefmetazole, cefotaxime, and cefepime) combined with glycopeptides for 34 randomly selected methicillin-resistant S. aureus (MRSA) isolates by three methods, including the checkerboard, time-killing, and combination MIC measurement methods. Thirteen SCCmec type III isolates with a cefazolin MIC of = 128 μg/mL were classified as the high-cefazolin MIC (HCM) group, whereas 13 SCCmec type IV and 8 SCCmec type V isolates were classified as the low-cefazolin MIC (LCM) group. With the checkerboard method, synergism was present for vancomycin-based combinations at 30.8-69.2 and 13.6-66.7%, as well as teicoplanin-based combinations of 38.5-84.6 and 0-47.6%, of the HCM and LCM isolates, respectively. No antagonism was noted. The in vitro inhibitory activity was evident even at a low concentration of 1/512x MIC of cephalosporin combined with sub-inhibitory concentrations (1/2x MIC) of a glycopeptide. With time-killing assays, synergism was noted at 1/2x or 1x susceptible breakpoint concentrations (SBCs) of a cephalosporin combined with 1/4 or 1/2 MIC of a glycopeptide. In the presence of 1/2 SBC of a cephalosporin, vancomycin or teicoplanin MICs decreased an average of 2.0- to 6.6- or 1.6- to 5.5-fold, respectively. With 8 μg/mL cephalosporin, the decline of glycopeptide MICs was most obvious in the presence of cefmetazole. In conclusion, cephalosporin-glycopeptide combinations at clinically achievable concentrations can exhibit in vitro synergistic antibacterial activity against clinical MRSA isolates. Such combinations require more clinical data to support their application for use in human MRSA infections.

KW - Cefazolin

KW - Cefepime

KW - Cefmetazole

KW - Cefotaxime

KW - Combination therapy

KW - Glycopeptides

KW - MRSA

KW - Synergism

UR - http://www.scopus.com/inward/record.url?scp=85019663695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019663695&partnerID=8YFLogxK

U2 - 10.3389/fmicb.2017.00884

DO - 10.3389/fmicb.2017.00884

M3 - Article

AN - SCOPUS:85019663695

VL - 8

JO - Frontiers in Microbiology

JF - Frontiers in Microbiology

SN - 1664-302X

IS - MAY

M1 - 884

ER -